![GSK spin-off to create consumer healthcare giant](https://www.berlinertageblatt.de/media/shared/articles/9d/4f/e5/GSK-spin-off-to-create-consumer-hea-959372.jpg)
-
Multiple people shot along highway in US state of Kentucky
-
'Super proud' Sabalenka downs Pegula to win US Open thriller
-
In Papua New Guinea, Pope holds mass 'at the edge of the world'
-
Hewett stays positive for wheelchair tennis despite agonising defeat
-
Three things on US Open champion Aryna Sabalenka
-
Sabalenka downs Pegula to win US Open thriller
-
USA men land Paralympic basketball three-peat, Jiang takes 7th swim gold
-
USA slump to first home defeat against Canada in 67 years
-
Argentina hand Australia record 67-27 loss in Rugby Championship
-
England impress on Carsley bow, Germany, Dutch hit five
-
AFP photographer wins top prize for Gaza coverage
-
No Love for Packers for three weeks after ligament sprain: reports
-
Pedro Almodovar: chronicler of modern Spain crowned in Venice
-
Almodovar wins top Venice prize for end-of-life film
-
Trump sounds dark tone at rally, Harris 'ready' for debate
-
Wirtz and Musiala dazzle to kick-start new Germany era
-
Chinese teenager takes 7th gold of Paris Paralympics
-
England interim boss Carsley 'respects' divided opinions over anthem
-
Neuville moves to the front in the Acropolis Rally
-
Garfield, Pugh charm Toronto in new romance 'We Live in Time'
-
21 boys confirmed dead in Kenya school inferno
-
Over 100,000 protest in France against new prime minister
-
Golden 30 minutes takes China to swimming Paralympics swimming domination
-
Green leads Australia to T20 series sweep of Scotland
-
Nigeria, Cameroon win afer chaotic AFCON build-ups
-
Nicole Kidman: A-lister, cinematic chameleon, wins in Venice
-
'I had to prove myself', says Kolisi after win against All Blacks
-
Almodovar wins top prize at Venice film festival
-
Grealish savours England redemption after 'worst summer'
-
Carsley makes flying start as England interim boss in win over Ireland
-
Springboks close on Rugby Championship with storming win over All Blacks
-
Sri Lanka's De Silva and Kamindu Mendis defy England in third Test
-
Farrell's Racing lose on opening day of Top 14
-
Ireland and UK to 'reset' relations as Starmer visits Dublin
-
Dunbar takes second Vuelta stage as Roglic closes in on victory
-
Fritz eyes US Open glory to end 21 years of American hurt
-
Thousands protest in France against new prime minister
-
Death toll from Kenya school blaze rises to 21
-
Brazil's right rallies for 'freedom' after X suspended
-
Trump to hold rally in swing state, Harris preps for debate
-
Stone at the double as Sri Lanka collapse against England in third Test
-
French tennis player takes legal action over online abuse
-
Italy backs Kyiv's 'legitimate defence' as Zelensky presses allies
-
The Body Shop rescued from administration after deal
-
Martin roars to victory in San Marino sprint, extends MotoGP lead
-
Smoke and screams: The horror of Kenya's school dorm inferno
-
MotoGP leader Martin roars to victory in San Marino sprint
-
Ireland and UK to 'reset' relations as Starmer begins Dublin visit
-
Ma Lin turns brutal encounter with bear into glorious Paralympic career
-
Flintoff appointed England Lions head coach
![GSK spin-off to create consumer healthcare giant](https://www.berlinertageblatt.de/media/shared/articles/9d/4f/e5/GSK-spin-off-to-create-consumer-hea-959372.jpg)
GSK spin-off to create consumer healthcare giant
British drugs giant GlaxoSmithKline on Monday demerges its newly-named consumer healthcare unit Haleon, resulting in what is set to be London's largest new stock market listing in more than a decade.
The new company -- owning brands including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu -- is set for a valuation of about £40 billion ($47.4 billion) when it begins trading on the London stock market, according to Bloomberg.
The major strategy shift by GSK chief executive Emma Walmsley comes after she has faced intense activist shareholder pressure over the company's delays in producing Covid jabs and treatments.
- 'Landmark London listing -
"This will be the largest London stock market listing in a decade, with the new company becoming a big beast with a new skin in the consumer goods world," said Susannah Streeter, senior investment and markets analyst at Hargreaves Lansdown.
It is set to be the capital's biggest listing since Swiss mining giant Glencore was valued at £38 billion on entry in 2011.
GSK, which owns 68 percent of Haleon, plans to retain six percent of the group following the spin-off.
US pharmaceutical titan Pfizer has said it plans to sell its 32-percent minority stake.
Walmsley, who had led the consumer unit prior to her promotion as head of GSK in 2017, has described the demerger as the group's most significant corporate change in 20 years.
The split sees GSK "parcelling off a considerable quantity of its sizeable debt pile into Haleon, expected to be around £10 billion", Streeter said.
Haleon could join London's top-tier FTSE 100 depending on its market valuation.
Walmsley, part of a group of less than 10 women chief executives running companies on the benchmark index, sees more long-term value in the demerger than a sale.
GSK at the start of the year rejected a £50 billion bid for the unit from consumer goods titan Unilever.
- Vaccine push -
Alongside the demerger, GSK is expanding further into the field of vaccines, having in May snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion.
Also this year, the British company spent $1.9 billion on US group Sierra Oncology, a specialist in medicines for rare forms of cancer.
Keith Bowman, analyst at Interactive Investor, said the demerger was aimed at giving GSK "increased management focus to each respective business".
This was the case "particularly for its pharma business which has underperformed rivals such as (Covid vaccine-maker) AstraZeneca over recent years", he told AFP.
GSK is set to receive £7 billion in dividends at separation.
The consumer healthcare division, whose portfolio of products includes also Centrum multivitamins and anti-inflammatory Voltaren, generates annual sales of about £10 billion.
Haleon will be headquartered in Weybridge, southwest of London.
"The idea is that a more focused consumer business will help boost sales," said Streeter.
"There will be no change at the top... which is a vote of confidence in Brian McNamara, a former Procter & Gamble executive who has led the division for eight years."
J.Fankhauser--BTB